Reuben Shaw Explained

Reuben Shaw
Nationality:American
Fields:CancerCell biologyMetabolism
Alma Mater:Cornell University (BS, Biology)Massachusetts Institute of Technology (PhD)
Academic Advisors:Tyler Jacks (MIT) and Lewis C. Cantley (Harvard)
Awards:Clarivate Top Cited Researcher (2019, 2020, 2021, 2022)NCI Outstanding Investigator Award (2017)Howard Hughes Medical Institute Early Career Scientist (2009)

Reuben Shaw is an American cancer researcher. He is a professor and director of the National Cancer Institute-Designated Cancer Center at the Salk Institute for Biological Studies, one of the NCI's seven basic laboratory cancer centers in the United States.[1] [2] [3] He researches signaling pathways that control tumor metabolism, with a specific focus on an ancient energy-sensing pathway that controls biological response to starvation.[4] [5]

Education

Reuben Shaw grew up in New York state, where he later earned a degree in biology from Cornell University.[6] Shaw then earned his Ph.D. in cancer biology at Massachusetts Institute of Technology with advisor Tyler Jacks. He completed his postdoctoral fellowship at Harvard Medical School with advisor Lewis C. Cantley.[7]

Career and research

In 2004, Reuben Shaw discovered a link between primitive energy-sensing AMP-activated protein kinase and tumor suppressing Lkb1.[8] In 2005, his lab showed that the type 2 diabetes drug Metformin operates by targeting both Lkb1 and AMP-activated protein kinase.[9] Since then, he has researched AMPK, its downstream targets, and how its molecular pathway functions in relation to diabetes and cancer.[10]

Shaw joined the Salk Institute for Biological Studies as an assistant professor in 2006. He became a professor at Salk in 2014 and currently holds the William R. Brody Chair. He is also currently an adjunct professor in molecular biology at University of California, San Diego.

Shaw has made a variety of discoveries related to the AMPK pathway:

Shaw uses a combination of genetic engineering in mice and interdisciplinary studies across cancer, diabetes, neurodegenerative disease, and aging.[15] [16] His research contributes to the development of therapeutic solutions to cancers and metabolic diseases, such as the pivot of Metformin to potentially treat cancers and the identification of LKB1 as a target for non-small-cell lung cancer treatments.[17]

Awards and honors

Notes and References

  1. Web site: Reuben Shaw, PhD . 2023-03-13 . Salk Institute for Biological Studies . en.
  2. Web site: Cancer Center Leadership . 2023-03-13 . Salk Institute for Biological Studies . en.
  3. Web site: 2012-04-05 . NCI-Designated Cancer Centers - NCI . 2023-08-08 . www.cancer.gov . en.
  4. Shackelford . David B. . Shaw . Reuben J. . 2009-08-01 . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression . Nature Reviews. Cancer . 9 . 8 . 563–575 . 10.1038/nrc2676 . 1474-1768 . 2756045 . 19629071.
  5. Web site: Meiling . Brittany . 2016-01-06 . Reuben Shaw Tapped to Lead Salk Cancer Center . 2023-03-13 . San Diego Business Journal . en-US.
  6. News: 2006-08-20 . Katja Lamia, Reuben Shaw . en-US . The New York Times . 2023-03-13 . 0362-4331.
  7. Web site: Reuben Shaw: A fated pathway . 2023-03-13 . The Scientist Magazine® . en.
  8. Shaw . Reuben J. . Kosmatka . Monica . Bardeesy . Nabeel . Hurley . Rebecca L. . Witters . Lee A. . DePinho . Ronald A. . Cantley . Lewis C. . 2004-03-09 . The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress . Proceedings of the National Academy of Sciences of the United States of America . 101 . 10 . 3329–3335 . 10.1073/pnas.0308061100 . 0027-8424 . 14985505 . 373461 . 2004PNAS..101.3329S . free .
  9. Web site: 2014-01-08 . Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer . 2023-03-13 . Leaders in Pharmaceutical Business Intelligence (LPBI) Group . en-US.
  10. Shaw . Reuben J. . 2006-12-01 . Glucose metabolism and cancer . Current Opinion in Cell Biology . 18 . 6 . 598–608 . 10.1016/j.ceb.2006.10.005 . 0955-0674 . 17046224.
  11. Web site: Worsley . Oliver . 2016-04-27 . Salk team IDs cell 'fuel gauge,' drawing important link in cancer and diabetes metabolism . 2023-03-13 . FierceBiotech.
  12. Goodwin . Jonathan M. . 2014-07-17 . A novel AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential . Molecular Cell . 55 . 3 . 436–450 . 10.1016/j.molcel.2014.06.021 . 25042806 . 4151130 .
  13. Shaw . Reuben J. . Lamia . Katja A. . Vasquez . Debbie . Koo . Seung-Hoi . Bardeesy . Nabeel . Depinho . Ronald A. . Montminy . Marc . Cantley . Lewis C. . 2005-12-09 . The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin . Science . 310 . 5754 . 1642–1646 . 10.1126/science.1120781 . 1095-9203 . 3074427 . 16308421. 2005Sci...310.1642S .
  14. Web site: Diabetes drug has unexpected, broad implications for healthy aging: Scientists discover multiple mechanisms at work in widely-used diabetes drug metformin . 2023-03-13 . ScienceDaily . en.
  15. Web site: 2014-01-08 . Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer . 2023-03-13 . Leaders in Pharmaceutical Business Intelligence (LPBI) Group . en-US.
  16. Web site: 2022-03-07 . Identification of Metabolic Targets and Vulnerabilities in Genetically-Defined Cohorts of Lung Cancer . 2023-03-13 . The Mark Foundation for Cancer Research . en-US.
  17. Shaw . Reuben . Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer . en.
  18. Web site: Highly Cited Researchers . 2023-03-14 . Clarivate . en.
  19. Web site: Past lists . 2023-03-14 . Clarivate . en.
  20. Web site: 2022-02-20 . Lustgarten Foundation awards $5 million for pancreatic cancer research . 2023-03-13 . Philanthropy News Digest.
  21. Web site: 2022-03-10 . Inspiring Collaboration in Cancer Research: The Mark Foundation for Cancer Research Announces 2022 Endeavor Award Recipients . 2023-03-16 . The Mark Foundation for Cancer Research . en-US.
  22. Web site: Curebound Who We Are . 2023-08-04 . www.curebound.org . en-US.
  23. Web site: August 25, 2017 . The ASCO Post Staff . Reuben Shaw, PhD, Receives NCI Outstanding Investigator Award - The ASCO Post . 2023-03-13 . ascopost.com . en.
  24. Web site: Howard Hughes Medical Institute 2011 Annual Report Researchers . 2023-08-04 . media.hhmi.org.
  25. Web site: Our Cancer Research Grants . 2023-03-14 . V Foundation . en-US.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Reuben Shaw".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.